One Patient at a Time
What Makes Us Different
We understand that our patients are in challenging situations.
That is why we take the utmost care in providing a safe, calming, spa-like facility that emanates positivity.
We Accept Most Major Insurances
What We Believe
Our mission is to cultivate psychological well-being through empathetic, patient-centered approaches to care.
What We Offer
- Spravato is the brand name for esketamine, an FDA-approved medication since March 2019 for the treatment of treatment-resistant depression (TRD) and Major Depression with suicidal ideation in adults. Treatment-resistant depression is characterized by a lack of adequate response to at least two different antidepressant treatments.
- For adults experiencing Major Depressive Disorder (MDD) who have attempted two or more antidepressants without success, Spravato presents itself as a viable option. Administered via nasal spray, it is meant to complement oral antidepressant therapy.
- Contemporary oral antidepressants are widely understood to alleviate depression by elevating neurotransmitter levels in specific brain regions that influence mood. In contrast, Spravato focuses on the N-Methyl-D-Aspartate (NMDA) receptor, representing a departure from the mechanisms of action seen in currently prescribed oral antidepressants.
- Esketamine, being the enantiomer of ketamine and an NMDA antagonist, operates by augmenting levels of the neurotransmitter glutamate and a growth factor known as BNDF.
- Spravato is not a pain reliever or an aesthetic.
- Side effects include dissociation, dizziness, nausea, sleepiness, feeling anxious, lack of energy, feeling very happy or excited. See the Spravato medication guide for complete safety information.
Get started today with
Paula-Ann Francis, M.D.
2022 Best of Weston: Best Psychiatrist